MIMS® Retrospective Chart Review

Minimally Invasive Micro Sclerostomy (MIMS®) Retrospective Chart Review

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06614218

Enrollment

Registered

2024-09-26

Start date

2025-02-01

Completion date

2026-01-01

Last updated

2025-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open Angle Glaucoma

Keywords

Polypharmacy, Intraocular Pressure, MIMS, Minimally Invasive Glaucoma Surgery, MIGS, MTMT, Trabeculectomy, Sclerostomy

Brief summary

This is a post-market clinical follow-up, retrospective chart review of MIMS® surgical procedures conducted during time period between Sep 2023 and May 2025.

Interventions

DEVICEMinimally Invasive Micro Sclerostomy

The MIMS® procedure uses the proprietary MIMS® device, which creates a sclerostomy in the eye.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to 85 Years

Inclusion criteria

1. Eye treated with MIMS® Device as a standalone procedure 2. MIMS® surgery was performed between 27 Sep 2023 and 30 April 2024

Design outcomes

Primary

Measure	Time frame
Change in IOP from medicated baseline at 12 months post-MIMS® surgery	Medicated baseline at 12 months post-MIMS® surgery
Change in the number of topical IOP-lowering medications from medicated baseline at 12 months post-MIMS® surgery	Medicated baseline at 12 months post-MIMS® surgery
Success rate at 12 months post-MIMS® surgery	12 months post-MIMS® surgery

Countries

Armenia

Contacts

Primary ContactKhan Lau, OD

khan@sanoculis.com8082862666

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026